Department of Surgical Oncology,
Osaka City University Medical School

1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585
PHONE; 06-6645-3838, FAX; 06-6646-6450

May 25, 2015

Science Editor, Editorial Office
Dear Professor Jing Yu,

Please find enclosed the edited manuscript in Word format (file name: 18787-review.doc).

ESPS Manuscript revision NO: 18787

Title: Fibroblast Growth Factor Receptor Signaling as Therapeutic Targets in Gastric Cancer
Author: Masakazu Yashiro and Tasuku Matsuoka

Name of Journal: *World Journal of Gastroenterology*

We greatly appreciate your invitation of re-submission of our manuscript (**ESPS** Manuscript revision NO: 18787) entitled "Fibroblast Growth Factor Receptor Signaling as Therapeutic Targets in Gastric Cancer" for publication in *World Journal of Gastroenterology*". We would like to thank the reviewers for helpful comments and suggestions for improvement in our manuscript. We have carefully considered the referee's comments, and the manuscript has been improved according to the suggestions of reviewers as described below. Also, we highlight changes in the revised manuscript.

We hope you will seriously consider this report for publication in *World Journal of Gastroenterology*.

Sincerely,

Masakazu Yashiro, MD, PhD
Department of Surgical Oncology, Osaka City University Graduate School of Medicine,
1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
TEL; (+81) 6-6645-3838
FAX; (+81) 6-6646-6450
e-mail address; m9312510@med.osaka-cu.ac.jp

1 Format has been updated.

2. A copy of signed statement should be provided to the BPG in PDF format.

3. Audio Core Tip is enclosing.

4. The graphs supplied as powerpoint format.

5 Revision has been made according to the suggestions of the reviewers as described below.

The manuscript has been improved according to the suggestions of reviewers:

Referee 00070894:

The authors provide an overview of FGFR signalling mechanisms and pathways on gastric cellular, and highlight the latest date on how FGFR signalling is being targeted therapeutically. This review is objectivity. The language is fluent. It is preferred that the issues could be clarified in a way of general comprehensive summary instead of lengthy explanation. And in my knowledge, there is FP-1039(gsk3052230) as FGF traps ongoing phase I clinical study in solid tumors. Is it appropriate to be included in this review?

Response: We revised text as comprehensive summary in EXPERIMENTAL STUDIES TARGETING FGFR SIGNALING IN GASTRIC CANCER session**. (page 6 line 3 -page 8 line 13).** We updated FP-1039(gsk3052230) as FGF traps ongoing phase I clinical study in solid tumors, as follows. FP-1039, also known as GSK3052230, is a protein drug designed to intervene in the FGF signaling through FGFR1 that stimulates cancer cell growth and angiogenesis. FP-1039 can bind to FGF ligands circulating in the extracellular space, preventing these signaling proteins from reaching FGFR1 on the surface of tumor cells. A phase IB trial to evaluate FP-1039 in combination with paclitaxel and carboplatin, or docetaxel in subjects with solid tumor, is ongoing (NCT01868022). **(page 7 line 22-27).**

Referee 00506590:

This is a deep and up-to-date review about targeting fibroblast growth factor receptor in the treatment of gastric cancer. A very well prepared manuscript that deserves to be published as it is.

Response: Thank you for your positive comments.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology.*

Sincerely yours,

Masakazu Yashiro, M.D., Ph. D.
Department of Surgical Oncology
Osaka City University Graduate School of Medicine
1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
Phone: 81-6-6645-3838; Fax: 81-6-6646-6450
e-mail: m9312510@med.osaka-cu.ac.jp